仁和药业：前三季度归母净利润3.79亿元 同比下降8.79%

Core Viewpoint - Renhe Pharmaceutical reported a revenue of 858 million yuan for Q3 2025, marking a year-on-year increase of 9.16%, with a net profit attributable to shareholders of 88.71 million yuan, up 13% [2] Financial Performance - For the first three quarters, the company achieved a revenue of 2.833 billion yuan, reflecting a year-on-year decline of 10.07% [2] - The net profit attributable to shareholders for the same period was 379 million yuan, down 8.79% year-on-year [2] - Basic earnings per share for Q3 2025 were 0.0634 yuan, while for the first three quarters, it was 0.2708 yuan [2]